Loading...
2019
Clinical impacts of inflammatory markers and clinical factors in patients with relapsed or refractory diffuse large B-cell lymphoma
Clinical impacts of inflammatory markers and clinical factors in patients with relapsed or refractory diffuse large B-cell lymphoma
대한혈액학회
논문정보
- Publisher
- Blood Research
- Issue Date
- 2019-12-20
- Keywords
- -
- Citation
- -
- Source
- -
- Journal Title
- -
- Volume
- 54
- Number
- 4
- Start Page
- 244
- End Page
- 252
- DOI
- ISSN
- 2287979X
Abstract
BackgroundSystemic inflammatory response can be associated with the prognosis of diffuse large B cell lymphoma (DLBCL). We investigated the systemic factors significantly related to clinical outcome in relapsed/refractory DLBCL.MethodsIn 242 patients with DLBCL, several factors, including inflammatory markers were analyzed. We assessed for the correlation between the survivals [progression-free surviv-al (PFS) and overall survival (OS)] and prognostic factors. ResultsIn these patients, a high derived neutrophil/lymphocyte ratio (dNLR) (PFS, HR=2.452, P=0.002; OS, HR=2.542, P=0.005), high Glasgow Prognostic Score (GPS) (PFS, HR=2.435, P=0.002; OS, HR=2.621, P=0.002), and high NCCN-IPI (PFS, HR=2.836, P=0.003; OS, HR=2.928, P=0.003) were significantly associated with survival in multi-variate analysis. Moreover, we proposed a risk stratification model based on dNLR, GPS, and NCCN-IPI, thereby distributing patients into 4 risk groups. There were significant differences in survival among the 4 risk groups (PFS, P<0.001; OS, P<0.001). ConclusionIn conclusion, dNLR, GPS, and NCCN-IPI appear to be excellent prognostic parameters for survival in relapsed/refractory DLBCL.
- 전남대학교
- KCI
- Blood Research
저자 정보
| 이름 | 소속 | ||
|---|---|---|---|
| 등록된 데이터가 없습니다. | |||